PROCLEIX® WNV Assay
FAQ
Only 20% of people infected with WNV are symptomatic; thus the vast majority do not know they are infected. Although donors may never develop symptoms of WNV infection, the virus may be present in their blood at sufficient levels to infect transfusion recipients. WNV NAT was designed for early detection of WNV infection in donors to prevent the transfusion of WNV-infected units in order to increase the safety of the blood supply.
Based on the initial call set forth by the FDA in October 2002, Novartis Diagnostics and Gen-Probe developed a flexible and robust assay to specifically detect West Nile virus. The PROCLEIX WNV Assay was designed to be performed on existing instrument platforms to minimize the operational impact of adding a new test and to enable ease of implementation.
Voluntary blood and plasma donors, including organ and tissue donors and non-heart beating donors.
See the Intended Use for details
(1.32 MB)
About Novartis Vaccines
Novartis Vaccines is a leader in providing products to fight more than 20 vaccine-preventable viral and bacterial diseases. Novartis Vaccines is the division researching novel treatments.